Evidence map›Paper›PMID 37772834›Full record

ArticleMicrobiology spectrum2023

Emergence of KPC-134, a KPC-2 variant associated with ceftazidime-avibactam resistance in a ST11

Xiangning Huang, Siquan Shen, Fan Chang, Xin Liu, Jinxi Yue, Ning Xie, Lin Yin, Fupin Hu, Daiwen Xiao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Resistance development in KPC-producingMicrobiology spectrum · 2026
    Article
  2. Article
  3. Article
  4. Shifting of blaBMC genomics · 2026
    Article
  5. Article
  6. Evolution of ceftazidime-avibactam resistance driven by variation inFrontiers in cellular and infection microbiology · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiangning Huang *Department of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China , Chengdu, China.
Siquan Shen *Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China.
Fan ChangDepartment of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China , Chengdu, China.
Xin LiuDepartment of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China , Chengdu, China.
Jinxi YueDepartment of Laboratory Medicine, Affiliated Hospital, North Sichuan Medical College , Nanchong, China.
Ning XieDepartment of Laboratory Medicine, Affiliated Hospital, North Sichuan Medical College , Nanchong, China.
Lin YinDepartment of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China , Chengdu, China.
Fupin HuInstitute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China.ORCID 0000-0002-4493-0619
Daiwen XiaoDepartment of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China , Chengdu, China.
University of Electronic Science and Technology of China · CNAffiliated Hospital of North Sichuan Medical College · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceThe emergence of various new KPC variants leading to ceftazidime-avibactam treatment failure is a new challenge for clinical anti-infection treatment. Here, we describe the characterization of a ceftazidime-avibactam-resistant blaKPC-134-positive

Indexed as

ceftazidime-avibactamKlebsiella pneumoniaeKPC-134

Identifiers

PMID37772834
PMCPMC10580995
OpenAlexW4387157604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.